<DOC>
	<DOCNO>NCT00154362</DOCNO>
	<brief_summary>Conduct disorder group psychiatric symptom include clinical characteristic impulsivity aggressive behavior . This study investigate efficacy safety oxcarbazepine treatment adolescent conduct disorder .</brief_summary>
	<brief_title>The Efficacy Safety Oral Oxcarbazepine 300-1200 mg/Day Adjuvant Therapy Treatment Adolescents With Impulsivity Aggressive Behavior Conduct Disorder This Study Not Being Conducted United States .</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Impulsive Behavior</mesh_term>
	<mesh_term>Conduct Disorder</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Oxcarbazepine</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>History conduct disorder , oppositional defiant disorder , disruptive behavior disorder otherwise specify Score &gt; 8 Impulsivity Rating Scale Other serious medical psychiatric condition exclude conduct disorder , oppositional defiant disorder , disruptive behavior disorder otherwise specify Treatment antiepileptic medication Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Oxcarbazepine , conduct disorder , adolescent</keyword>
</DOC>